This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Zacà, V. Articles by Dei Cas, L. Search for Related Content PubMed PubMed Citation Articles by Zacà, V. Articles by Dei Cas, L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Pulmonary Hypertension Hazardous Substances DB THIOPHENE Social Bookmarking                         What's this?

Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade

Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy

Marco Metra

Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy, metramarco{at}libero.it

Rossella Danesi

Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy

Carlo Lombardi

Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy

Giulia Verzura

Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy

Livio Dei Cas

Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy

Pulmonary arterial hypertension (PAH) is a rare but well-known cardiovascular condition potentially associated with human immunodeficiency virus (HIV) infection and is currently recognized to be one of the most ominous noninfectious HIV complications. Although there is no clear evidence supporting the use of any medication for the treatment of HIV-related PAH, many of the currently available agents have been shown to exert some clinical benefits HIV-PAH patients. To date, no data are available regarding the potential effects of sitaxsentan, a selective endothelin type-A receptor antagonist, in this peculiar patient population. We report the case of a successful switch to sitaxsentan in a HIV-infected patient with PAH initially receiving bosentan who developed a late treatment-related side-effect.

Key Words: HIV infection • pulmonary arterial hypertension • endothelin receptor antagonists • sitaxsentan

Therapeutic Advances in Respiratory Disease, Vol. 3, No. 1, 11-14 (2009)
DOI: 10.1177/1753465808101549


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?